[ALDX] Aldeyra Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.85 Change: 0.15 (3.19%)
Ext. hours: Change: 0 (0%)

chart ALDX

Refresh chart

Strongest Trends Summary For ALDX

ALDX is in the long-term down -64% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Aldeyra Therapeutics, Inc. develops drug candidates for capturing and removing free aldehydes to treat and prevent diseases, and slow the progression of chronic disease. The company?s products target immune-mediated, inflammatory, orphan, and other diseases. It develops NS2, a compound that binds and traps free aldehydes. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Burlington, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS-1.91 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-2.25
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-48.5% ROE-55.88% ROI
Current Ratio15.35 Quick Ratio Long Term Debt/Equity0.07 Debt Ratio0.07
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities9.04 M Cash From Investing Activities Cash From Operating Activities-1.84 M Gross Profit
Net Profit-2.14 M Operating Profit-2.11 M Total Assets15.93 M Total Current Assets15.9 M
Total Current Liabilities1.04 M Total Debt1.26 M Total Liabilities2.1 M Total Revenue
Technical Data
High 52 week14.35 Low 52 week5.16 Last close5.21 Last change-3.52%
RSI47.88 Average true range0.3 Beta0.82 Volume13.12 K
Simple moving average 20 days-3.59% Simple moving average 50 days-13.96% Simple moving average 200 days-34.81%
Performance Data
Performance Week-4.23% Performance Month-9.08% Performance Quart-32.77% Performance Half-34.22%
Performance Year-27.13% Performance Year-to-date-37.23% Volatility daily2.49% Volatility weekly5.56%
Volatility monthly11.39% Volatility yearly39.45% Relative Volume214.91% Average Volume253.42 K
New High New Low

News

2020-06-04 08:00:00 | Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease

2020-06-03 09:04:01 | Ironwood Pharmaceuticals IRWD Looks Good: Stock Adds 7.6% in Session

2020-06-03 08:00:00 | Aldeyra Therapeutics to Present at the Jefferies Virtual Healthcare Conference

2020-05-27 09:49:57 | 3 “Strong Buy” Biotech Stocks Under $5 With Explosive Upside Potential

2020-05-27 02:37:46 | Edited Transcript of ALDX earnings conference call or presentation 7-May-20 12:00pm GMT

2020-05-20 17:24:33 | Covid Report: This Biotech Says Its Coronavirus Drug Topped Remdesivir

2020-05-20 08:12:06 | The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

2020-05-20 07:00:00 | Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch Meeting

2020-05-20 01:48:22 | Aldeyra Explodes 30% After-Hours Ahead Of Covid-19 Update Today

2020-05-19 16:05:00 | Aldeyra Therapeutics to Host Conference Call and Webcast to Provide COVID-19 Development Update

2020-05-15 08:53:12 | How Aldeyra ALDX Stock Stands Out in a Strong Industry

2020-05-14 10:14:02 | Top Ranked Momentum Stocks to Buy for May 14th

2020-05-13 12:00:04 | Aldeyra Therapeutics Inc ALDX Upgraded to Strong Buy: Here's What You Should Know

2020-05-13 08:17:12 | Aldeyra's Shares March Higher, Can It Continue?

2020-05-07 07:00:00 | Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs

2020-04-30 08:00:00 | Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update

2020-04-16 06:35:12 | These Mass. companies are developing COVID-19 treatments and tests

2020-04-15 09:47:01 | Company News for Apr 15, 2020

2020-04-14 08:00:00 | Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629

2020-03-24 12:00:04 | What Makes Aldeyra Therapeutics, Inc. ALDX a New Buy Stock

2020-03-24 08:00:00 | Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection

2020-03-18 06:13:27 | Chair of the Board Richard Douglas Just Bought Shares In Aldeyra Therapeutics, Inc. NASDAQ:ALDX

2020-03-12 16:39:34 | Edited Transcript of ALDX earnings conference call or presentation 12-Mar-20 12:00pm GMT

2020-03-12 07:00:00 | Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones

2020-03-12 06:59:00 | Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Disease

2020-03-05 08:00:00 | Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Fourth-Quarter and Full-Year 2019 Financial Results and Corporate Update

2020-03-03 08:00:00 | Aldeyra Therapeutics to Present at the Oppenheimer & Co. 30th Annual Healthcare Conference

2020-02-24 08:00:00 | Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day

2020-02-11 08:00:00 | Aldeyra Therapeutics to Host 2020 Research & Development Day

2020-01-28 08:00:00 | Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board

2020-01-21 08:00:00 | Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis

2020-01-14 08:00:00 | Aldeyra Therapeutics Appoints Nancy Miller-Rich to Board of Directors

2019-12-21 07:07:11 | The CEO, President & Director of Aldeyra Therapeutics, Inc. NASDAQ:ALDX, Todd Brady, Just Bought 8.7% More Shares

2019-12-19 08:00:00 | Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 GUARD Trial for Prevention of Proliferative Vitreoretinopathy

2019-12-13 15:07:12 | Hedge Funds Are Selling Aldeyra Therapeutics Inc ALDX

2019-12-03 12:42:49 | Investors question Lexington startup's dry eye treatment

2019-12-03 07:59:26 | The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

2019-12-03 07:13:00 | Aldeyra Therapeutics announces positive early results in trial of dry eye disease treatment

2019-12-03 07:00:00 | Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

2019-12-02 16:01:00 | Aldeyra Therapeutics to Host Conference Call and Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

2019-11-14 13:08:53 | Edited Transcript of ALDX earnings conference call or presentation 7-Nov-19 1:00pm GMT

2019-11-12 08:00:00 | Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences

2019-11-07 07:00:00 | Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones

2019-11-01 08:00:00 | Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update

2019-10-31 07:00:00 | Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis

2019-10-30 16:01:00 | Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis

2019-10-21 08:02:11 | Does The Aldeyra Therapeutics, Inc. NASDAQ:ALDX Share Price Fall With The Market?

2019-10-13 16:33:09 | The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings

2019-10-07 08:00:00 | Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting

2019-09-26 08:00:00 | Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting